Global efforts to curb viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a novel report from the World Health Organization (WHO). While coordinated international action has led to significant declines in certain infection rates, the agency warns that the current pace of progress is insufficient to meet the ambitious 2030 elimination targets.
The 2026 Global Hepatitis Report, released on April 28, 2026, highlights a critical tension: the availability of highly effective medical tools versus a systemic failure in delivery. Viral hepatitis, specifically types B and C, continues to claim lives at a staggering rate, often because patients remain undiagnosed until the disease has progressed to advanced liver cirrhosis or cancer. The WHO report indicates that these two strains are responsible for more than 95% of deaths related to viral hepatitis.
For health professionals and policymakers, the data serves as both a proof of concept and a call to urgency. The report demonstrates that when political commitment and funding are aligned, elimination is possible. However, for millions of people in underserved regions, the gap between the existence of a cure and the access to that cure remains a lethal barrier.
Measuring the Gains: A Decade of Progress
Since countries adopted hepatitis elimination targets at the 2016 World Health Assembly, there have been quantifiable improvements in global health outcomes. The 2026 report outlines a decade of gains, most notably a 32% drop in new hepatitis B infections and a 12% decline in hepatitis C-related deaths. Official WHO data shows that these trends are the result of scaled-up vaccination programs and the introduction of more effective antiviral therapies.
One of the most significant successes has been observed in pediatric health. Among children under five, the prevalence of hepatitis B has fallen to 0.6%. According to the report, 85 countries have already met or exceeded the 2030 target of 0.1% for this demographic, proving that birth-dose vaccination strategies can effectively break the cycle of mother-to-child transmission.
The report cites several nations as blueprints for success. Egypt, Georgia, Rwanda and the UK have demonstrated that sustained investment and integrated health strategies can move a country toward the total elimination of viral hepatitis. These examples serve as evidence that the 2030 goals are not merely aspirational but achievable with the right domestic funding and political will.
The Burden of Disease: 2024 Statistics
Despite these gains, the sheer volume of the global burden remains overwhelming. In 2024, an estimated 287 million people were living with chronic hepatitis B or C. The human cost of this burden is reflected in the mortality rates; hepatitis B and C caused 1.34 million deaths in 2024. WHO statistics reveal that transmission remains widespread, with approximately 4,900 new infections occurring every day, totaling 1.8 million annually.
The distribution of these infections and deaths is starkly uneven:
- Hepatitis B: Accounted for 0.9 million new infections in 2024, with 68% of these cases occurring in Africa. The report notes a critical gap in prevention in this region, where only 17% of newborns received the essential birth-dose vaccine.
- Hepatitis C: Likewise saw 0.9 million new infections in 2024. A significant driver of this transmission is the lack of harm reduction services, as people who inject drugs accounted for 44% of these new cases.
- Mortality Concentration: A small number of countries bear a disproportionate burden of the death toll. Ten countries, including Bangladesh, China, India, Nigeria, and the Philippines, accounted for 69% of all hepatitis B deaths.
The report further clarifies that deaths from hepatitis C are more widely distributed globally, with high totals recorded in China, India, Japan, Pakistan, and the United States.
The Treatment Gap: Cure vs. Access
Perhaps the most troubling finding in the 2026 report is the disparity between the medical ability to treat these diseases and the actual delivery of care. For hepatitis C, a 12-week therapy exists with a cure rate of approximately 95%. Yet, since 2015, only 20% of patients have been treated. The WHO report emphasizes that this gap is not due to a lack of science, but a lack of access.
The situation for hepatitis B is even more precarious. While long-term antiviral treatments can manage chronic infection and prevent the progression to liver cancer, fewer than 5% of the 240 million people with chronic hepatitis B received treatment in 2024. This lack of care contributed to 1.1 million deaths from hepatitis B and 240,000 from hepatitis C in 2024 alone.
The WHO attributes this failure to several systemic factors. Tedros Adhanom Ghebreyesus, Director General at WHO, noted that progress remains uneven because many individuals remain undiagnosed or untreated. He identified stigma, weak health systems, and unequal access to care as the primary drivers of this disparity. The Director General emphasized that scaling up prevention, diagnosis, and treatment is now an urgent necessity to avoid missing the 2030 targets entirely.
Tereza Kasaeva, contributing to the report’s findings, stressed that missed diagnoses are leading to preventable deaths. She advocated for the integration of hepatitis services into primary care to ensure that affected communities, particularly those in marginalized populations, can be reached before the disease reaches a terminal stage.
Pathways to 2030: What Must Change
To bridge the gap between current progress and the 2030 goals, the WHO is calling for a rapid expansion of healthcare infrastructure. The report specifically urges expanded treatment for hepatitis B in Africa and the Western Pacific, and wider access to hepatitis C care in the Eastern Mediterranean. The full Global Hepatitis Report 2026 provides a framework for countries to accelerate their response.
The WHO’s recommended strategy focuses on five key pillars:
- Strengthening Political Commitment: Moving hepatitis from a secondary health concern to a primary national priority with dedicated domestic funding.
- Universal Birth-Dose Vaccination: Increasing the coverage of the hepatitis B vaccine for newborns to prevent lifelong chronic infection.
- Expanding Mother-to-Child Prevention: Implementing stricter measures to stop the transmission of HBV from mother to child during birth.
- Harm Reduction: Expanding safe injection practices and services for people who inject drugs to curb the spread of hepatitis C.
- Primary Care Integration: Moving testing and treatment out of specialized clinics and into community-based primary health centers to increase screening rates.
The agency also points to the efficacy of existing tools as a reason for optimism. Vaccines that protect more than 95% of people against hepatitis B are readily available, and the short-course therapies for hepatitis C are among the most successful antiviral treatments in medical history. The challenge is no longer one of innovation, but of logistics and equity.
Key Takeaways from the 2026 Global Hepatitis Report
- Measurable Success: New hepatitis B infections have dropped by 32% and hepatitis C deaths have declined by 12% over the last decade.
- Pediatric Gains: 85 countries have met the 2030 target for hepatitis B prevalence in children under five (below 0.1%).
- Lethal Gaps: 1.34 million people died from viral hepatitis in 2024, with a heavy concentration of HBV deaths in Africa and the Western Pacific.
- Treatment Failure: Less than 5% of people with chronic hepatitis B received treatment in 2024, despite the availability of effective antivirals.
- Urgent Need: WHO calls for integrated primary care and stronger political will to reach the 2030 elimination targets.
As the international community moves closer to the 2030 deadline, the focus now shifts to the implementation of the Consolidated guidance and implementation handbook on hepatitis B and C
released by the WHO in March 2026 to help countries expand their service delivery. The next major evaluation of these efforts will occur as countries report their mid-term progress toward the Sustainable Development Goals.
Do you believe your local healthcare system is doing enough to screen for silent killers like viral hepatitis? Share your thoughts and experiences in the comments below.